On Demand 2016 - Asthma in 2016: Advances in Understanding Origin, Presentation and Approaches to Management (MOC)

You can earn up to 1.0 AMA PRA Category 1 Credit(s)™. This activity has also been designated by the ABAI for 1.0 MOC Part II Self-Assessment credits. 

The role of respiratory viruses and the respiratory microbiome in patients who have persistent asthma is an important topic in understanding the origin of asthma. This discussion will form the basis for recognizing various treatment modalities that may be applied to children with mild to moderate asthma. This will lead into a discussion of how biologics should be appropriately used in the treatment of asthma that does not respond to GINA Step 3, 4 and 5 care, as well as the pros and cons of the two classes of biologic agents that are available.

Release Date: 12/01/2016
Expiration Date: 11/30/2019

Accreditation

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Learning Objectives

  • Describe the role of viruses and bacteria in asthma inception and how infectious agents could serve as potential targets for asthma prevention
  • Discuss common asthma phenotypes among preschool children and how treatment response to common asthma therapies may be different among these phenotypes
  • Appropriately identify who will benefit from biologic therapy to decrease burden of disease in a cost-effective manner
Additional information
Disclosure: 
  • Chitra Dinakar, MD, FACAAI, Moderator – Consultant/Advisor: Meda, Teva; Speaker: Boehringer Ingelheim, Teva
  • James Gern, MD – Consultant/Advisor: Janssen, Prep Biopharma Inc, Regeneron
  • Leonard B. Bacharier, MD, FACAAI – Consultant/Advisor: Boehringer Ingelheim, DBV Technologies, Genentech, Meda, Merck, Novartis, Sanofi, Teva, Vectura; Speaker: AstraZeneca, Boehringer Ingelheim, Merck, Teva
  • John J. Oppenheimer, MD, FACAAI – Consultant/Advisor: AstraZeneca, Genentech, GlaxoSmithKline, Meda, Mylan, Novartis, Annals of Allergy, ABAI, Up to date, Teva; Supported/ Contracted Research: AstraZeneca, Genentech, MedImmune, Sanofi
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
  • 1.00 MOC
Course opens: 
12/01/2016
Course expires: 
11/30/2019
Cost:
$24.00
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
  • 1.00 MOC

Accreditation Period

Course opens: 
12/01/2016
Course expires: 
11/30/2019

Price

Cost:
$24.00
Please login or create an account to take this course.